Gilead Sciences Raises Fiscal Year Product Sales Forecast
July 29 2021 - 5:20PM
Dow Jones News
By Kimberly Chin
Gilead Sciences Inc. raised the upper end of its full-year
product sales target range, as the company saw a strong first half
of the year for its products.
The biopharmaceutical company now expects total product sales
between $24.4 billion and $25 billion, compared with its prior view
of $23.7 billion to $25.1 billion.
Gilead expects sales of Veklury to be in the range of $2.7
billion to $3.1 billion, up from its previous projection of $2
billion to $3 billion, reflecting the longer than expected effect
of the coronavirus pandemic on its HIV business, the company said.
Veklury's sales tend to be affected by Covid-19-related rates of
infections, hospitalizations and vaccinations.
On a GAAP basis, it expects full-year earnings around $4.70 to
$5.05 a share, lower than its previous guidance of $4.75 to $5.45 a
share. The company expects adjusted earnings around $6.90 to $7.25
a share, compared with its prior outlook of $6.75 to $7.45 a
share.
Gilead's shares slipped 2.2% after hours to $68.30.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
July 29, 2021 17:17 ET (21:17 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024